USPTO grants ReST Therapeutic’s Patent on PTSD
[et_pb_section fb_built=”1″ _builder_version=”4.9.9″ _module_preset=”default” custom_padding=”0px|||||”][et_pb_row _builder_version=”4.9.9″ _module_preset=”default” min_height=”441px” custom_margin=”|auto|-73px|auto||”][et_pb_column type=”4_4″ _builder_version=”4.9.9″[…]
A new patent for Biotech ReST Therapeutics as part of its search for solutions against Post-Traumatic Syndrome and Alzheimer’s
[et_pb_section fb_built=”1″ _builder_version=”4.9.9″ _module_preset=”default”][et_pb_row _builder_version=”4.9.9″ _module_preset=”default”][et_pb_column _builder_version=”4.9.9″ _module_preset=”default” type=”4_4″][et_pb_text _builder_version=”4.9.9″ _module_preset=”default”[…]
FENM facilitates extinction learning without sensorimotor deficits
International Journal of Neuropsychopharmacology, 2021 Jul 14;24(6):519-531. https://doi.org/10.1093/ijnp/pyab007 Fluoroethylnormemantine, A Novel[…]
ReST Results on Alzheimer to be presented at AD/PD 2021
Dr. Tangui Maurice of Montpellier University and ReST's scientific partner will[…]
First Results on FENM published in International Journal of Neuropsychopharmacology
FENM appeared as a potent neuroprotective drug in an AD model,[…]